Cardiovascular diseases (CVD) are the leading cause of death in the world,[1] with increasing numbers of cases in low
and middle-income countries. In Brazil, it is estimated that 350,000 patients die each
year due to CVD.[2] The relationship
between acute coronary syndrome (ACS) and peripheral atherosclerotic disease (PAD) is
well established.[3,4]Cross-sectional studies carried out in countries with genetic characteristics different
from ours help us to evaluate the possible relationship between the characteristics of
the patients evaluated and the increase in cardiovascular risk, and, despite their
limitations, are good hypothesis generators.The present study[5] analyzed the
characteristics of patients with ACS and PAD, showing that advanced age, diabetes, worse
lipid profile and multiarterial disease were more prevalent in patients with ACS and PAD
than in patients with ACS and without PAD. In addition, it suggested that patients with
such an association have a worse prognosis.Limitations of the present study were the facts of its retrospective analysis and the
exclusion of patients at higher risk (prior acute myocardial infarction, acute
myocardial infarction caused by thrombus detachment, intravascular surgery, patients
with cardiogenic shock and post-cardiac arrest and gastrointestinal bleeding on
admission), which could have shown an even higher risk in such patients, considering
that generally patients with associated PAD have greater complications and worse
prognosis. It is also worth noting that it was carried out in a single center.However, the present study has great value for showing once again, as previous studies
have demonstrated,[6] the worsening of
the prognosis of patients with ACS and PAD and which risk factors are most prevalent in
this population, making possible the detection of subgroups of patients with ACS and PAD
are more susceptible to a worse outcome and in this way emphasize their strict control.
It is also necessary to offer the best treatment evidenced in the literature to such
patients since real-life studies have shown that despite the higher risk of patients
with ACS and PAD, they frequently receive less drugs with established benefit.[7]
Authors: Filipa Cordeiro; Pedro S Mateus; Alberto Ferreira; Silvia Leao; Miguel Moz; J Ilidio Moreira Journal: Eur Heart J Acute Cardiovasc Care Date: 2017-06-19
Authors: Taku Inohara; Karen Pieper; Daniel M Wojdyla; Manesh R Patel; William Schuyler Jones; Pierluigi Tricoci; Kenneth W Mahaffey; Stefan K James; John H Alexander; Renato D Lopes; Lars Wallentin; Erik Magnus Ohman; Matthew T Roe; Sreekanth Vemulapalli Journal: Am Heart J Date: 2018-03-28 Impact factor: 4.749
Authors: Luyan Zhang; Yaling Tian; Hong Ren; Aihong Zhu; Li Dong; Xiuqin Wang; Xiaoyu Han Journal: Comput Math Methods Med Date: 2022-07-21 Impact factor: 2.809